
2026 Set to Be a Pivotal Year for Obesity Medications
By 2026, two new oral obesity pills from Novo Nordisk and Eli Lilly are expected to hit the U.S. market, offering a more convenient alternative to injections and potentially capturing a significant share of the growing weight loss drug market, with prices expected to be lower than current injectable options.